Rhythm Pharmaceuticals reported encouraging six-month Phase 2 trial results for setmelanotide in patients with Prader-Willi syndrome, showing improvements in BMI, body composition, hyperphagia, and behavior. The study involved 18 patients aged 6 to 23, with 17 still on treatment, revealing a mean BMI reduction of about 3% and clinically meaningful improvements in hunger and anxiety symptoms. Safety remained consistent with previous findings. The ongoing trial will continue through 52 weeks, with more data expected.
A class action lawsuit has been filed against Nano-X Imaging Ltd. and some of its officers, accusing them of making false and misleading statements about the company's operations and prospects between March 31, 2025, and April 17, 2026. The lawsuit c...
TripAdvisor has agreed to sell its European restaurant reservation platform, TheFork, to American Express for $700 million in cash. TheFork generated $232 million in revenue and $28 million in adjusted EBITDA in the past year. This sale supports Trip...
The sulfuric acid market is projected to grow from $41.23 billion in 2025 to $49.94 billion by 2030 at a CAGR of 3.9%. Growth is driven by rising demand in metal processing, especially for base metals used in construction, electronics, and renewable ...
Smart Clerk, an AI-powered bookkeeping platform, has surpassed 6,000 small business users who rely on its tools to simplify bookkeeping and generate tax-ready reports. The platform recently enhanced its connectivity by integrating with financial data...
SpaceX shares have surged above $170 shortly after its IPO, surpassing two of three early analyst price targets. Initial targets ranged from $165 to $190, with the stock closing near $161 on the first day and rising to around $170 by the second day. ...
